These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22795090)

  • 21. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
    Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metronomic therapy: chemotherapy revisited.
    Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
    Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metronomic chemotherapy in ovarian cancer.
    Garg V; Kumar L
    Cancer Lett; 2023 Nov; 579():216469. PubMed ID: 37923056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose metronomic chemotherapy with cisplatin enhanced immunity in a murine model of ectopic cervical cancer.
    Tsai CC; Qiu JT; Tseng CW; Hsu YC
    Clin Exp Pharmacol Physiol; 2016 Feb; 43(2):251-8. PubMed ID: 26541904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
    Eskander RN; Tewari KS
    Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
    Husseinzadeh N; Husseinzadeh HD
    Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
    Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
    Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor endothelial cells as a potential target of metronomic chemotherapy.
    Kim JY; Kim YM
    Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
    Kim MK; James J; Annunziata CM
    BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The Near-Future of Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer].
    Nagao S
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):198-202. PubMed ID: 27093731
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of chemotherapy in epithelial ovarian cancer.
    Markman M
    Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can targeted therapy be successful without metronomic scheduling?
    André N; Pasquier E; Kamen B
    Curr Top Med Chem; 2012; 12(15):1639-42. PubMed ID: 22978340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metronomics chemotherapy: time for computational decision support.
    Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Outpatient chemotherapy in gynecologic oncology].
    Jobo T
    Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():369-71. PubMed ID: 17469390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ovarian cancer: targeting the untargetable.
    Birrer MJ
    Am Soc Clin Oncol Educ Book; 2014; ():13-5. PubMed ID: 24857054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
    Munoz R; Shaked Y; Bertolini F; Emmenegger U; Man S; Kerbel RS
    Breast; 2005 Dec; 14(6):466-79. PubMed ID: 16199161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.